

بسم الله الرحمن الرحيم





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكرو فيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحتفظ هذه الأقراص المدمجة بعيدا عن الغبار





Egyptian Experience of Rituximab Use in Neuromyelitis Optica

Thesis

*Submitted for Partial Fulfilment of the
Master Degree in Neurology & Psychiatry*

By

Nouran Gamal Ezzeldin Mowafy

M.B.B.Ch, Faculty of Medicine, Ain Shams University

Supervised by

Prof. Dr. Hany Mohamed Amin Aref

Professor of Neurology

Faculty of Medicine, Ain Shams University

Prof. Dr. Azza Abdel Nasser Abdel Aziz Saeed

Professor of Neurology

Faculty of Medicine - Ain Shams University

Prof. Dr. Dina Mohamed Abdel Gawad Zamzam

Professor of Neurology

Faculty of Medicine - Ain Shams University

*Faculty of Medicine
Ain Shams University*

2021

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبَدَانِكَ لَا عِلْمَ لَنَا
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Hany Mohamed Amin Aref**, Professor of Neurology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Dr. Azza Abdel Masser Abdel Aziz Saeed**, Professor of Neurology, Faculty of Medicine, Ain Shams University, for her sincere efforts, valuable instructions, fruitful encouragement, constant help and great assistance throughout this work.*

*I am deeply thankful to **Prof. Dr. Dina Mohamed Abdel Gawad Zamzam**, Professor of Neurology, Faculty of Medicine, Ain Shams University, for her great help, outstanding support, active participation and guidance.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Nouran Gamal Ezzeldin Mowafy

List of Contents

Title	Page No.
List of Tables.....	i
List of Figures	iv
List of Abbreviations.....	vi
Introduction	1
Aim of the Work	4
Review of Literature	
▪ Epidemiology and Pathogenesis of Neuromyelitis Optica	5
▪ Clinical Picture of Neuromyelitis Optica.....	14
▪ Management of Neuromyelitis Optica.....	32
▪ Riuximab Use in Neuromyelitis Optica.....	44
Patients and Methods.....	48
Results.....	50
Discussion	80
Summary.....	87
Conclusion	91
References	92
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Prevalence of Neuromyelitis optica globally	8
Table 2:	NMOSD diagnostic criteria for adult patient	17
Table 3:	Features of typical and atypical optic neuritis	20
Table 4:	Main causes of immune-mediated optic neuritis	21
Table 5:	Comparison between Percentage (number of patients) and percentage (number of patients) discontinuing AZA because of side effects regarding side effects	37
Table 6:	Description of the gender of patients among study group.....	50
Table 7:	Description of the mean age of patients (years) at onset at time of study, age at disease onset in (years) and Consanguinity.	51
Table 8:	Description of the Co-morbid autoimmune diseases and Family history of immune-mediated diseases	53
Table 9:	Description of the Serum Aquaporin 4 Ab and Visual Evoked Potential in all study patients	54
Table 10:	Comparison between the EDSS before and after treatment with rituximab	55
Table 11:	Comparison between MRI brain, thoracic spine and cervical spine before and after treatment with rituximab.....	57
Table 12:	Comparison between the ARR before and after treatment with rituximab	58
Table 13:	Showing incidence of different adverse events	59

List of Tables *cont...*

Table No.	Title	Page No.
Table 14:	Description of Clinical improvement regarding EDSS and radiological improvement after to treatment with rituximab.....	61
Table 15:	Comparison between occurrence of complications and other patient's characteristics	63
Table 16:	Comparison between occurrence of complications and Co-morbid autoimmune diseases and Family history of immune-mediated diseases	64
Table 17:	Comparison between occurrence of complications and EDSS before and after treatment with rituximab	65
Table 18:	Comparison between occurrence of complications and Serum Aquaporin 4 Ab and Visual Evoked Potential	66
Table 19:	Comparison between ARR and occurrence of complications before and after treatment with rituximab	67
Table 20:	Comparison between EDSS before and after treatment with rituximab and other patient's characteristics	68
Table 21:	Comparison between EDSS before and after treatment with rituximab and patient's Co-morbid autoimmune diseases and Family history of immune-mediated diseases	69
Table 22:	Comparison between EDSS before and after treatment with rituximab and its relation with Serum Aquaporin 4 Ab and Visual Evoked Potential	70

List of Tables *cont...*

Table No.	Title	Page No.
Table 23:	Comparison between EDSS improvement and magnetic resonance imaging before and after treatment with rituximab, whether it is the thoracic spine, cervical spine, or the brain	71
Table 24:	Comparison between EDSS and ARR before and after treatment with rituximab.....	74
Table 25:	Comparison between radiological improvement before and after treatment with rituximab and other patient's characteristics.....	75
Table 26:	Comparison between radiological improvement before and after treatment with rituximab and patient's Co-morbid autoimmune diseases and Family history of immune-mediated diseases.....	76
Table 27:	Comparison between radiological improvement before and after treatment with rituximab and Serum Aquaporin 4 Ab as well as Visual Evoked Potential.....	77
Table 28:	Comparison between radiological improvement before and after treatment with rituximab and the EDSS.....	78
Table 29:	Comparison between radiological improvement before and after treatment with rituximab and ARR	79

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Potential role of B cells in neuromyelitis optica pathogenesis.....	12
Figure 2:	NMOSD immunopathogenesis.....	12
Figure 3:	Optic nerve MRI patterns in neuromyelitis optica spectrum disorder	19
Figure 4:	Typical spinal cord involvement in NMOSD	25
Figure 5:	Sagittal T2-weighted fluid-attenuated inversion recovery (FLAIR) MRI.....	27
Figure 6:	Variety of brain lesion patterns are associated with neuromyelitis optica spectrum disorder	29
Figure 7:	Description of the gender of patients among study group	50
Figure 8:	Description of the Consanguinity	52
Figure 9:	Description of the Co-morbid autoimmune diseases and Family history of immune-mediated diseases	53
Figure 10:	Description of the Serum Aquaporin 4 Ab in all study patients	54
Figure 11:	Description of the Visual Evoked Potential in all study patients	55
Figure 12:	A Comparison between the EDSS before and after treatment with rituximab	56
Figure 13:	Comparison between the ARR before and after treatment with rituximab	58
Figure 14:	Showing incidence of different adverse events....	59
Figure 15:	Showing complications of transient infusion related adverse effects, upper respiratory tract infection, urinary tract infection and lymphopenia.....	60
Figure 16:	Description of Clinical improvement regarding EDSS after to treatment with rituximab.....	61

List of Figures cont...

Fig. No.	Title	Page No.
Figure 17:	Description of Clinical improvement regarding radiological improvement after to treatment with rituximab.	62
Figure 18:	Comparison between occurrence of complications and Serum Aquaporin 4 Ab and Visual Evoked Potential	66
Figure 19:	Comparison between not improved EDSS and improved EDSS regarding magnetic resonance imaging before treatment	72
Figure 20:	Comparison between not improved EDSS and improved EDSS regarding magnetic resonance imaging after treatment	72
Figure 21:	Comparison between not improved EDSS and improved EDSS regarding magnetic resonance imaging thoracic spine after treatment	73

List of Abbreviations

Abb.	Full term
AQP4-Ab	Aquaporin-4 autoantibody
ARR	Annualized relapse rate
AZA	Azathioprine
BBB	Blood–brain barrier
CNS	Central nervous system
CSF	Surrounding cerebrospinal fluid
EDSS	Expanded Disability Status Scale
FLAIR	Fluid-attenuated inversion recovery
IL-6	Interleukin-6
INF- γ	Interferon gamma
IPND	International Panel for NMO Diagnosis
IVMP	Intravenous methylprednisolone
LETM	Longitudinally extensive transverse myelitis
LVEF	Left ventricular ejection fraction
mAb	Monoclonal antibody
MG	Myasthenia gravis
MMF	Mycophenolate Mofetil
MPA	Mycophenolic acid
MSIF	Multiple Sclerosis International Federation
MTX	Methotrexate
NMO	Neuromyelitis optica
NMOSD	Neuromyelitis optica spectrum disorder
OCT	Optical coherence tomography
ON	Optic neuritis
PAG	Periaqueductal grey
PIMND	Patients with immune-mediated neurological disorders

List of Abbreviations *cont...*

Abb.	Full term
PLEX	Plasma exchange
PRES	Posterior reversible encephalopathy syndrome
SIADH	Syndrome of inappropriate antidiuretic hormone secretion
SLE	Systemic lupus erythematosus
SPSS	Statistical package for Social Science
SS	Sjögren syndrome
STM	Short transverse myelitis
TM	Transverse myelitis
VA	Visual acuity
VEP	Visual evoked potentials
VF	Visual field

INTRODUCTION

Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune inflammatory disease of the central nervous system with preferential involvement in the optic nerve and spinal cord with a widespread spectrum of clinical features from which recovery is often incomplete, thus resulting in residual and accumulating impairment (*Wingerchuk et al., 2015*).

The epidemiology of NMOSD is not clearly established because the disease is frequently misdiagnosed as MS. The reported incidence and prevalence of NMOSD are dependent on geographical location and ethnicity. African ancestry is at increased risk, with high mortality rates. The incidence and prevalence of NMOSD ranges from 0.05–0.40 and 0.52–4.4 per 100,000 people respectively (*Mori et al., 2018*).

As with many autoimmune diseases, females are more susceptible than males (3:1–9:1). The median age at presentation is 39 years, but 15–20% of patients may present to pediatricians (under 16 years) or elderly care physicians (greater than 65 years). Clustering of NMOSD in families is rare but recognized, suggesting complex genetic susceptibility (*Huda et al., 2019*).

A NMOSD case series study in Egypt showed that despite some limitations in testing and access to care, there are features of NMOSD population that appear to be different from other worldwide cohorts reported in literature. These